Expression and Clinical Significance of CAS in Acute Myeloid Leukemia Patients.
10.19746/j.cnki.issn.1009-2137.2022.03.013
- Author:
Hao-Ran GUO
1
;
Xin WANG
2
;
Han ZHANG
2
;
Kun-Ping GUAN
3
Author Information
1. Second Clinical Medical College of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.
2. Department of Laboratory Medicine, Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.
3. Department of Laboratory Medicine, Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China,E-mail: guankunping5135@126.com.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
cellular apoptosis susceptibility;
prognosis
- MeSH:
Bone Marrow/metabolism*;
Cellular Apoptosis Susceptibility Protein/metabolism*;
Humans;
Ki-67 Antigen/metabolism*;
Leukemia, Myeloid, Acute/drug therapy*;
Prognosis;
Remission Induction
- From:
Journal of Experimental Hematology
2022;30(3):744-749
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the expression of cellular apoptosis susceptibility protein （CAS） in acute myeloid leukemia （AML） and its correlation with clinical characteristics.
METHODS:The expression of CAS in bone marrow tissue of 54 patients with AML and 24 patients with non-hematological malignant diseases was detected by Western blot and immune-histochemical method, and compared between AML group and control group. Also the relationship of CAS expression in AML and sex, age, WBC count, Hb, platelet count, bone marrow blast cell ratio, ki-67 index, cytogenetic and molecular biological prognostic risk stratification, extramedullary infiltration and other clinical characteristics was analyzed.
RESULTS:Western blot showed that the expression of CAS protein in bone marrow biopsies of AML patients was significantly higher than that in control group (P<0.05). Immune-histochemical method revealed that CAS was mainly located in the cytoplasm in both AML group and control group. Among 54 AML patients, 14 patients (25.9%) showed high expression of CAS, while all the 24 patients in the control group showed low expression of CAS. The high expression rate of CAS in AML patients was significantly higher than that in the control group (P<0.05). There were statistically significant differences in prognostic risk stratification and the remission rate of the first chemotherapy between CAS high expression group and CAS low expression group in AML (P<0.05). The proportion of high risk patients and unremission patients after the first chemotherapy in CAS high expression group were significantly higher than those in CAS low expression group (57.1% vs 27.5%, 30.8% vs 7.9%), while the proportion of low risk patients and complete remission patients after the first chemotherapy were significantly lower than those in CAS low expression group (14.3% vs 37.5%, 53.8% vs 84.2%). In AML patients, the ki-67 index of bone marrow tissue in CAS high expression group was higher than that in CAS low expression group (60% vs 50%) (P<0.05).
CONCLUSION:CAS is localized in cytoplasm in both AML and non-hematological malignant diseases, and its expression increases in AML. CAS is related to the risk stratification of cytogenetics and molecular biology, the remission rate after the first chemotherapy and ki-67 index in AML, which suggests that CAS may be involved in the occurrence and development of AML.
